Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis) - Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis)

Additional Information

Field	Value
Data last updated	October 20, 2025
Metadata last updated	October 20, 2025
Created	October 20, 2025
Format	HTML
License	Open Government Licence - Canada
Has views	False
Id	5ca33a82-54d3-44ef-a19f-c7f3144a0737
Package id	baefaeba-5cf5-4c75-9251-b138f65872ea
Position	1
State	active